Panasonic Professional Video & Audio Systems Names Caroline Niedzwiecki as Director of Sales
NEWARK, N.J.--(BUSINESS WIRE)--Panasonic Entertainment & Communication Co., Ltd. today announced that Caroline Niedzwiecki has been appointed as director of sales. In this role, Caroline will oversee the company's audio and video business, which includes Panasonic's suite of Pan-Tilt-Zoom (PTZ), studio, and box cameras, camcorder portfolio, media production and audio solutions, and the KAIROS Live Video Production Platform.
"The company's mission resonates with my passion for leveraging technology to deliver meaningful experiences. I'm excited to work with Panasonic's high-performing sales team."
Niedzwiecki brings more than 25 years of experience in the professional AV and M&E industry, with a strong background in business development and sales leadership. She most recently served as the general manager and vice president at disguise where she spent three years leading the company's North and South American sales. Prior to disguise, she was the vice president of global sales at BirdDog and senior vice president of business development at NewTek (now a Vizrt company) where she spent nearly a decade leading their sales expansion in North America, EMEA, and the successful launch of NDI products globally.
She also held positions at Avid Technology Inc. and was a member of SVGW (formerly Women's Sports Media Initiative), an organization focused on enhancing the role of women in the creation, production and distribution of sports content.
'Panasonic's commitment to delivering glass-to-glass solutions allows its customers to fundamentally enhance the way people work, live, and experience live events,' said Caroline Niedzwiecki, Director of Sales, Panasonic Professional Video & Audio Systems. 'The company's mission resonates with my passion for leveraging technology to deliver meaningful experiences. I'm excited to work with Panasonic's high-performing sales team as the broadcast industry continues to undergo rapid transformation and becomes more reliant on scalable, interoperable technology to meet consumer demands.'
As director of sales, Niedzwiecki will maintain, grow, and build new relationships with customers and partners across corporate, higher education, house of worship, broadcast, sports, and live events. Her deep knowledge of the audiovisual industry allows her to lead high-performing teams with a clear purpose that keeps them focused on delivering tailored solutions to meet each customer's unique needs.
With the professional AV market experiencing rapid growth, Niedzwiecki is committed to driving long-term growth for Panasonic and helping its customers understand the value of investing in unified communications.
About Panasonic Entertainment & Communication Co., Ltd.
Panasonic Entertainment & Communication Co., Ltd. established in April 2022 as part of the Panasonic Group's switch to an operating company system, is strengthening the bonds among people and enriching our customers' lives by providing consumer electronics, including AVC products such as OLED TVs, Lumix digital cameras, headphones, phones, intercoms, and more, as well as business products and solutions including for broadcast, professional AV, and sound systems globally. Our mission is to offer people new emotion and relaxation through our entertainment and communication solutions. To fulfill this mission, we strive to act with professionalism to continuously recreate the future by connecting people. For more details, please visit https://www.panasonic.com/global/peac.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Tom's Guide
3 hours ago
- Tom's Guide
Surprise! Get this 65-inch Panasonic OLED TV for under $1,000 in rare Amazon deal
Father's Day might be over, but the TV deals are still hot. With sports seasons still in full swing, Dad will want the best seat in the house for all of his favorite content — and I think I've found the perfect pick. Right now, you can get the Panasonic Z85A OLED TV for $997 at Amazon. That's a 45% slashing on this 2024 display and one of the lowest price we've seen in a while. Panasonic TVs are making a comeback in the US Built around Panasonic's HCX Pro AI Processor MKII, its new OLED TV offers support for HDR10/HDR10+/Dolby Vision/HLG and Dolby Atmos audio. On the gaming front, you get a 120Hz panel with VRR, AMD FreeSync Premium, and NVIDIA G-Sync support. It comes in 55- and 65-inch size options. Beyond netting you incredible picture performance for the NBA Finals, the Panasonic Z85A OLED TV is also packed with tons of value. It's built on Fire TV, giving you access to a slew of streaming services and even one of the best cloud gaming services in Xbox Game Pass. It's also built on a 120Hz refresh rate with a range of HDR compatibility. This includes HDR10, HDR10+, Dolby Vision, and HLG, plus you even have Dolby Atmos to steep you even deeper into immersive movie nights. What makes the Z85A truly stand out is its audio performance. Few TVs really deliver sound with such punchy weightiness, but the Z85A not only has a 50W speaker but also a 20W woofer and even two 15W drivers, all of which are built on a 2.1-channel system. No need for one of the best soundbars. And, while it might already have its fair share of cloud gaming, it's also got a ton of gaming features built into the panel. This makes it ideal for everything from the PS5 Pro to the new Nintendo Switch 2. Panasonic wouldn't return to the US market for nothing. It brought just two OLEDs and this is marked as an utter steal if you're still looking to get in on a new TV.
Yahoo
4 hours ago
- Yahoo
Trump Mobile: President's Company Unveils Wireless Service Delivered via AT&T, Verizon and T-Mobile, Plans to Launch a U.S.-Made ‘Sleek, Gold' Android Smartphone
President Trump and his family are getting into the wireless business, in partnership with the three major U.S. carriers. The Trump Organization on Monday announced Trump Mobile, which will offer 5G service with an unlimited plan (the '47 Plan') priced at $47.45 per month. The new venture joins the lineup of the company's other businesses, which span luxury hotels, golf clubs, casinos, retail and and other real estate properties. The president's two oldest sons, Donald Trump Jr. and Eric Trump, made the announcement at a press conference at Trump Tower in Manhattan. More from Variety Shakira Says Being an Immigrant in the United States Means 'Living in Constant Fear': 'The Treatment of All People Must Always Be Humane' Jimmy Kimmel, Kerry Washington, Ayo Edebiri Join 'No Kings' Protests Against Trump Administration: 'Love One Another. It Really Is as Simple as That' Trump Lawyers Confirm They Are in 'Active Settlement Discussions' With Paramount Over President's '60 Minutes' Lawsuit Customers can switch to Trump Mobile's T1 Mobile service using their current phone. In addition, in August, Trump Mobile plans to release the 'T1 Phone' — described as 'a sleek, gold smartphone engineered for performance and proudly designed and built in the United States for customers who expect the best from their mobile carrier.' 'Trump Mobile is going to change the game,' Donald Trump Jr. said in a statement. 'We're building on the movement to put America first, and we will deliver the highest levels of quality and service. Our company is based right here in the United States because we know it's what our customers want and deserve.' Trump Mobile functions as a mobile virtual network operator, or MVNO, offering 5G service through the three U.S. major wireless carriers — A&T, Verizon and T-Mobile USA. Other examples of MVNOs include Consumer Cellular and Ryan Reynold's Mint Mobile. Trump Mobile and its carrier partners are subject to regulatory oversight by the Federal Communications Commission, which is headed by Trump-appointed FCC chairman Brendan Carr. The Trump T1 Phone, which runs Google's Android operating system, will cost $499. It features a 6.8-inch touch-screen with a 120 Hz refresh rate. The smartphone also has a 'fingerprint sensor and AI Face Unlock,' according to the company's website. Trump Mobile didn't immediately respond to an inquiry about what company is manufacturing the Android phone. The Trump Organization said Trump Mobile's customer-service team is based in the United States and available 24 hours a day. 'When customers call, they're talking to a real person,' according to the company. The Trump Mobile '47 Plan' benefits include: 'complete device protection'; 24-hour roadside assistance through Drive America; free international calling to more than 100 countries; telehealth services, including virtual medical care, mental health support and ordering of prescription medications. The plan does not require subscribers to sign any contracts, and there are no credit checks required, according to Trump Mobile. Trump Mobile's site also includes a disclaimer stating that it is 'not liable for service interruptions, delays, or damages caused by third-party providers outside of our direct control.' More details are available at For 2024, Trump reported more than $600 million in income, including about $57.4 million from the World Liberty Financial cryptocurrency platform, according to a mandatory financial disclosure form released Friday by the Office of Government Ethics. (The disclosure form does not include income he generated from the $TRUMP meme coin, which was released in January 2025.) As of Feb. 20, 2025, Trump owned 114.75 million shares of Trump Media & Technology Group (which operates Truth Social) through a revocable trust, representing 52% of total outstanding shares; those holdings are currently worth more than $2.2 billion. Ahead of Monday's announcement, the Trump Organization had said, 'On June 16, 2025, Donald Trump Jr. and Eric Trump will return to the iconic Trump Tower to celebrate the 10-year anniversary of their father famously coming down the escalator and announcing to the world that he was running for President of the United States. Ten years later, they will make a major announcement of a new initiative the Trump Organization is launching that will change the game once again.' Best of Variety New Movies Out Now in Theaters: What to See This Week 'Harry Potter' TV Show Cast Guide: Who's Who in Hogwarts? 25 Hollywood Legends Who Deserve an Honorary Oscar Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 85th Scientific Sessions
– Hengrui to present six abstracts highlighting clinical progress of GLP-1/GIP dual receptor agonist HRS9531 (KAI-9531) and GLP-1 receptor agonist HRS-7535 (KAI-7535) in type 2 diabetes and obesity – JIANGSU, China and BOSTON, June 16, 2025 (GLOBE NEWSWIRE) -- Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions, today announced the presentation of six abstracts at the 85th Scientific Sessions of the American Diabetes Association (ADA), taking place June 20-23, 2025, in Chicago, IL. The presentations will highlight the breadth of the companies' metabolic disease portfolio, including data from several clinical-stage injectable and oral therapies. Data presented will cover results from clinical trials sponsored and conducted by Hengrui for an injectable GLP-1/GIP receptor dual agonist HRS9531 (in development as KAI-9531 outside of Greater China), an oral small molecule GLP-1 receptor agonist HRS-7535 (KAI-7535), and an oral formulation of HRS9531 (KAI-9531). The following abstracts were submitted by Hengrui and accepted for presentation: HRS9531Oral presentation: Friday, June 20, 5:45-6:00 p.m. CT Phase 2 clinical trial of HRS9531 in participants with type 2 diabetes up to 32 weeks Abstract 126-OR: Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist in Participants with Type 2 Diabetes Mellitus Up to 32 Weeks Posters: Sunday, June 22, 12:30-1:30 p.m. CT Phase 1 clinical trial of HRS9531 (oral peptide) in healthy participants Abstract 797-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 Tablet, an Oral Dual GLP-1/GIP Receptor Agonist, in Healthy Participants: A Phase 1 Study Phase 2 clinical trial of HRS9531 in adults with obesity without diabetes up to 52 weeks Abstract 853-P: Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist (HRS9531), in Obese Adults without Diabetes: Up to 52-Week Treatment Phase 2 clinical trial of HRS9531 high dose (8 mg) in adults with obesity or overweight without diabetes Abstract 874-P: Efficacy and Safety of a Novel Dual GLP-1/GLP Receptor Agonist in Chinese Overweight or Obese Adults without Diabetes HRS-7535Posters: Sunday, June 22, 12:30-1:30 p.m. CT Phase 2 clinical trial of HRS-7535 in adults with type 2 diabetes Abstract 837-P: Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (HRS-7535) in Type 2 Diabetes Mellitus Patients Inadequately Controlled by Metformin Phase 2 clinical trial of HRS-7535 in adults with obesity without diabetes Abstract 865-P: Efficacy and Safety of a Novel Oral Small Molecule GLP-1RA in Chinese Obese Adults without Diabetes All abstracts will be published online in the journal Diabetes® and presentations will be accessible on the Scientific Publications section of the Kailera website following the congress. Additional information can be found on the ADA website. About Hengrui PharmaJiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. With a global R&D team that includes 14 R&D centers and more than 5,500 professionals, Hengrui Pharma's therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. To date, Hengrui has commercialized 23 new molecular entity drugs and 4 other innovative drugs in China. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. About Kailera TherapeuticsKailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera's most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that has demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera's mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health. The Company is based in Waltham, MA and San Diego, CA. For more information, visit and follow us on LinkedIn and X. Contact Information for Hengrui PharmaDGA Grouphengrui@ Contact Information for KaileraMaura GavaghanVice President, Corporate Communications and Investor
